Advertisement
UK markets close in 1 hour 2 minutes

  • FTSE 100

    8,053.93
    +13.55 (+0.17%)
     

  • FTSE 250

    19,569.54
    -149.83 (-0.76%)
     

  • AIM

    752.81
    -1.88 (-0.25%)
     

  • GBP/EUR

    1.1654
    +0.0009 (+0.08%)
     

  • GBP/USD

    1.2492
    +0.0030 (+0.24%)
     

  • Bitcoin GBP

    51,026.39
    -1,641.04 (-3.12%)
     

  • CMC Crypto 200

    1,377.13
    -5.45 (-0.39%)
     

  • S&P 500

    5,010.15
    -61.48 (-1.21%)
     

  • DOW

    37,810.03
    -650.89 (-1.69%)
     

  • CRUDE OIL

    82.30
    -0.51 (-0.62%)
     

  • GOLD FUTURES

    2,335.70
    -2.70 (-0.12%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,829.75
    -258.95 (-1.43%)
     

  • CAC 40

    7,976.32
    -115.54 (-1.43%)
     
Stocks:

Trending tickers

Microsoft, Alphabet, Anglo American, IBM, Astrazeneca, Unilever and Sainsbury's

Merck KGaA to continue testing cancer vaccine

Reuters - UK Focus

FRANKFURT, Sept 25 (Reuters) - Germany's Merck KGaA (Other OTC: MKGAY - news) said it would start a new study testing its experimental lung cancer vaccine Stimuvax, which fell through in a previous late-stage trial.

Merck said on Tuesday it would test the drug, which it licensed from U.S. biotech firm Oncothyreon (NasdaqGS: ONTY - news) , on patients with locally advanced Stage III non-small cell lung cancer (NSCLC), which cannot be surgically removed.

Stimuvax, also known as Tecemotide, failed to improve survival in a pivotal study in December, dealing a blow to the company and the high-risk field of using vaccines to fight tumours.

Merck said on Tuesday that data from an analysis of a predefined patient subgroup in this trial, however, showed some promise. (Reporting by Ludwig Burger)